/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

A

A.B. El-Khoueiry

University of Southern California(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

9

Papers

12

Citations

2

h-index

0

i10-index

A.B. El-Khoueiry is an academic researcher from University of Southern California. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Immunotherapy and Immune Responses. The author has an h-index of 2, co-authored 8 publications.

Research Topics

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Immunotherapy and Immune Responses Monoclonal and Polyclonal Antibodies Research Colorectal Cancer Treatments and Studies

Papers by this author

works

691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation

2024 · Annals of Oncology · 4 citations

https://doi.org/10.1016/j.annonc.2024.08.2162

Alison M. Schram Gilberto Lopes A.B. El-Khoueiry Elisa Fontana

625P Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications

2024 · Annals of Oncology · 2 citations

https://doi.org/10.1016/j.annonc.2024.08.692

Marwan Fakih Davendra Sohal Justin Call Susanna V. Ulahannan

9O Phase I/II, open-label, first-in-human study of the anti-GPC3 T cell engager SAR444200 in patients with advanced solid tumors: Updated safety and pharmacokinetic analysis

2025 · ESMO Open · 2 citations

https://doi.org/10.1016/j.esmoop.2025.104165

K. Almhanna Jung Yong Hong Maxime Chénard-Poirier B-Y. Ryoo

1011P Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors

2024 · Annals of Oncology · 0 citations

https://doi.org/10.1016/j.annonc.2024.08.1070

D. Roda Perez Jon Zugazagoitia Elena Garralda Alexander I. Spira

P2.06.100 Initial Biomarker Results From the Phase 2A Study of AFM24 With Atezolizumab in Patients With Advanced/Metastatic NSCLC

2025 · Journal of Thoracic Oncology · 0 citations

https://doi.org/10.1016/j.jtho.2025.09.634

H.R. Kim A. Oberoi Juanita Lopez A.B. El-Khoueiry

947P First-in-class CBL-B inhibitor NX-1607: Phase Ia data in patients with advanced solid tumors

2025 · Annals of Oncology · 0 citations

https://doi.org/10.1016/j.annonc.2025.08.1516

A. Williams Adam Sharp T.R.J. Evans Simon Pacey

Research topics

topics

Cancer Immunotherapy and Biomarkers

CAR-T cell therapy research

Immunotherapy and Immune Responses

Monoclonal and Polyclonal Antibodies Research

Colorectal Cancer Treatments and Studies

Chat about Author

Papers

Chat

Click to start Chat